ETFs Holding ACOR »    ACOR Historical Stock Prices »
ACOR News Video: Wed, Jun 21, 2017, 10:31 AM — Wednesday 6/21 Insider Buying Report: ACOR, SBBX

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Acorda Therapeutics is a biopharmaceutical company focused on developing therapies for neurological disorders. Co.'s marketed therapies include: Ampyra, an extended release tablet formulation of dalfampridine for the treatment of multiple sclerosis (MS); and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. Co. has a pipeline of neurological therapies addressing a range of disorders, including Parkinson's disease and MS. Co.'s research and development program include SYN120, which is a potential treatment for Parkinson's-related dementia; and BTT1023 (timolumab), a product candidate for the orphan disease Primary Sclerosing Cholangitis. Self directed investors in Acorda Therapeutics Inc will be interested in keeping up with all Acorda Therapeutics Inc news they can find, both ACOR news originating from the company in the form of press releases, as well as seeing how independent media outlets are reporting news on ACOR. At RediNews, we simplify this task by presenting both ACOR news releases originating from Acorda Therapeutics Inc itself, and ACOR news from a variety of media outlets. Visitors can browse this news online and through our ACOR RSS news feed.


ACOR News — Articles, Videos, & Press Releases

Acorda Therapeutics Enters Oversold Territory (ACOR)
Monday, April 15, 2019, 4:36 PM — Dividend Channel
First Week of ACOR May 17th Options Trading
Tuesday, March 19, 2019, 11:47 AM — Stock Options Channel
Implied SLY Analyst Target Price: $76
Tuesday, March 19, 2019, 7:27 AM — ETF Channel
Acorda Therapeutics Becomes Oversold
Wednesday, February 20, 2019, 4:30 PM — Dividend Channel
Acorda (ACOR) Q4 Earnings and Revenues Surpass Estimates
Friday, February 15, 2019, 9:29 AM — Zacks
Analysts Anticipate IJS To Hit $169
Friday, February 15, 2019, 8:20 AM — ETF Channel
Acorda Therapeutics (ACOR) Tops Q4 Earnings and Revenue Estimates
Thursday, February 14, 2019, 4:25 PM — Zacks
First Week of ACOR March 15th Options Trading
Monday, January 28, 2019, 10:42 AM — Stock Options Channel
Vertex Terminates COO Ian Smith on Code of Conduct Violation
Thursday, January 24, 2019, 9:46 AM — Zacks
Vertex's Orkambi Wins EU Nod to Treat Cystic Fibrosis in Kids
Tuesday, January 22, 2019, 8:31 AM — Zacks
Aerpio (ARPO) Jumps: Stock Rises 7.8%
Tuesday, January 22, 2019, 7:39 AM — Zacks
How The Pieces Add Up: PBE Headed For $65
Tuesday, January 15, 2019, 8:46 AM — ETF Channel
First Week of February 15th Options Trading For Acorda Therapeutics (ACOR)
Thursday, January 3, 2019, 11:38 AM — Stock Options Channel
Noteworthy Friday Option Activity: ACOR, GPRO, AAPL
Friday, December 14, 2018, 3:19 PM — Stock Options Channel
Add Up The Pieces: PWC Could Be Worth $113
Wednesday, December 12, 2018, 8:13 AM — ETF Channel
Noteworthy Tuesday Option Activity: UAL, ALGN, ACOR
Tuesday, December 4, 2018, 3:26 PM — Stock Options Channel
Short Interest In Acorda Therapeutics Moves 12.3% Higher
Wednesday, November 28, 2018, 3:43 PM — Market News Video
Analysts Anticipate MMTM Will Reach $139
Wednesday, October 24, 2018, 8:17 AM — ETF Channel
Short Interest Moves 13% Higher For ACOR
Wednesday, October 10, 2018, 2:21 PM — Market News Video
Interesting ACOR Put And Call Options For November 16th
Monday, October 8, 2018, 10:33 AM — Stock Options Channel
Relative Strength Alert For Acorda Therapeutics
Friday, October 5, 2018, 12:46 PM — Dividend Channel
Commit To Buy Acorda Therapeutics At $12, Earn 40.8% Annualized Using Options
Tuesday, October 2, 2018, 11:47 AM — Stock Options Channel
Look Under The Hood: PBE Has 13% Upside
Thursday, September 13, 2018, 7:56 AM — ETF Channel
Noteworthy Monday Option Activity: ALNY, ACOR, EROS
Monday, September 10, 2018, 3:18 PM — Stock Options Channel
Oversold Conditions For Acorda Therapeutics
Monday, September 10, 2018, 11:55 AM — Dividend Channel
ACOR Crosses Below Key Moving Average Level
Monday, September 10, 2018, 11:52 AM — Market News Video
Notable Thursday Option Activity: ACOR, JBT, PCRX
Thursday, July 26, 2018, 3:24 PM — Stock Options Channel
RSI Alert: Acorda Therapeutics (ACOR) Now Oversold
Wednesday, July 25, 2018, 4:30 PM — Dividend Channel
Notable Friday Option Activity: ACOR, DE, HRTX
Friday, June 22, 2018, 3:19 PM — Stock Options Channel
Notable Friday Option Activity: UBNT, AAOI, ACOR
Friday, June 8, 2018, 3:26 PM — Stock Options Channel
Acorda Therapeutics Reaches Analyst Target Price
Friday, May 25, 2018, 8:11 AM — ETF Channel
Bullish Two Hundred Day Moving Average Cross - ACOR
Thursday, May 24, 2018, 11:55 AM — Market News Video
Noteworthy Monday Option Activity: HBI, STMP, ACOR
Monday, April 30, 2018, 3:20 PM — Stock Options Channel
ACOR is categorized under the Healthcare sector; below are links to news for some other companies in the same sector:


RediNews invites those seeking web page financial content for any internet portal, especially any vertical portal specializing in the markets where there is a web page for business, web page for markets, web page finance, etc., to integrate our free web site content, our RSS news feeds. These RSS feeds are found throughout our website wherever news and custom stock content is found, by clicking the RSS icon for any news page (which will look like this): . This dynamic financial content is ideal for sites that already feature stock data content such as historical stock price information whether in the form of a historical stock price table or a web page chart image, to supplement the other custom stock market content displayed.

ACOR News | | Copyright © 2013 - 2019, All Rights Reserved

Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.